Tratamiento no hormonal del síndrome genitourinario de la menopausia Non-hormonal treatment of genitourinary syndrome of menopause

Contenido principal del artículo

Franklin José Espitia de la Hoz
https://orcid.org/0000-0002-4581-9680

Resumen

El síndrome genitourinario de la menopausia (SGUM) describe los síntomas y signos vulvo-vaginales y del tracto urinario inferior, de carácter crónico y progresivo, secundario a un estado clínico de hipoestrogenismo que caracteriza a la postmenopausia.
La presente revisión tiene como objetivo describir y analizar las diferentes alternativas terapéuticas no hormonales, con sus ventajas y desventajas, a fin de ofrecerle a los lectores una completa variedad de opciones a la hora de establecer el tratamiento en
una mujer con SGUM. Se ha realizado una búsqueda en bases de datos, incluyendo
investigaciones originales, consensos de expertos, revisiones sistemáticas y metaanálisis.
Se ha revisado la evidencia actual para diversas modalidades terapéuticas farmacológicas
y no farmacológicas (no hormonales), encontrando que los hidratantes y los lubricantes son la primera línea terapéutica para proporcionar alivio, a corto plazo, de la sequedad vaginal (leve a moderada) y la dispareunia; sin embargo, el tratamiento ha de
ser individualizado. Existen numerosos tratamientos disponibles, cada uno con beneficios y limitaciones y se destacan las sustanciales lagunas, en la evidencia científica, de terapias seguras y efectivas, así como la necesidad de realizar investigaciones futuras.

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Sección
Artículos de Revisión de Tema
Biografía del autor/a

Franklin José Espitia de la Hoz, Director Científico: Hathor, Clínica Sexológica. Armenia, Quindío

Especialista Ginecología y Obstetricia, Universidad Militar Nueva Granada. Uroginecología y cirugía reconstructiva del piso pélvico / UNal, FUCS, Unicamp (Brasil). Máster en Sexología: Educación y asesoramiento sexual, Universidad de Alcalá de Henares. Fellow of the American College of Ginecology and Obstetric. Presidente de la Asociación Colombiana de Menopausia (Eje Cafetero). Director Científico: Hathor, Clínica Sexológica. Armenia, Quindío.

Citas

Portman DJ, Gass ML. Genitourinary syndrome

of menopause: new terminology for vulvovaginal

atrophy from the International Society for

the Study of Women’s Sexual Health and The

North American Menopause Society. Menopause.

; 21(10):1063–8.

DOI: 10.1097/GME.0000000000000329

Espitia-De La Hoz FJ, Orozco-Gallego H. Estriol

vs estrógenos conjugados de origen equino

en el tratamiento del síndrome genitourinario

de la menopausia. Ginecol Obstet Mex. 2018;

(2):117-26.

https://doi.org/10.24245/gom.v86i2.1881

Moral E, Delgado JL, Carmona F, Caballero B,

Guillán C, González PM, et al. Genitourinary

syndrome of menopause. Prevalence and

quality of life in Spanish postmenopausal

women. The GENISSE study. Climacteric. 2018;

(2):167-73.

https://doi.org/10.1080/13697137.2017.1421921

Nappi RE, Kokot-Kierepa M. Vaginal health:

insights, views and attitudes (VIVA) – results

from an international survey. Climacteric. 2012;

(1):36–44.

https://doi.org/10.3109/13697137.2011.647840

Espitia-De La Hoz FJ. Prevalence of genitourinary

syndrome of menopause and impact on sexuality

of women in Quindío (Colombia), 2013-2016. Rev

Colomb Obstet Ginecol. 2018; 69(4):249-259.

http://dx.doi.org/10.18597/rcog.3111

The North American Menopause Society. The 2020

genitourinary syndrome of menopause position

statement of The North American Menopause

Society. Menopause. 2020; 27(9):976-992.

http://dx.doi.org/10.1097/GME.0000000000001609

Stumpf PG, Trolice MP. Compliance problems with

hormone replacement therapy. Obstet Gynecol

Clin North Am. 1994; 21(2):219-229.

Espitia-De La Hoz FJ, Orozco-Gallego H. Abordaje

diagnóstico y terapéutico del síndrome genitourinario

en la menopausia; actualización. Rev Med

UCR. 2017; 11(2):67-84.

https://doi.org/10.15517/rmucr.v11i2.34580

Palacios S, Mejía A, Neyro JL. Treatment of the

genitourinary syndrome of menopause. Climacteric.

; 18 (Suppl 1):23-29.

http://dx.doi.org/10.3109/13697137.2015.1079100

Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B,

et al. Genitourinary syndrome of menopause: an

overview of clinical manifestations, pathophysiology,

etiology, evaluation, and management. Am

J Obstet Gynecol. 2016; 215(6):704-711.

DOI: 10.1016/j.ajog.2016.07.045

Leiblum S, Bachmann G, Kemmann E, Colburn D,

Swartzman L. Vaginal atrophy in the postmenopausal

woman. The importance of sexual activity

and hormones. JAMA. 1983; 249(16):2195-

Mercier J, Morin M, Zaki D, Reichetzer B, Lemieux

MC, Khalifé S, et al. Pelvic floor muscle training

as a treatment for genitourinary syndrome of

menopause: A single-arm feasibility study. Maturitas.

; 125:57-62.

https://doi.org/10.1016/j.maturitas.2019.03.002

Edwards D, Panay N. Treating vulvovaginal

atrophy/genitourinary syndrome of menopause:

how important is vaginal lubricant and

moisturizer composition? Climacteric. 2016;

(2):151-161.

https://doi.org/10.3109/13697137.2015.1124259

Bygdeman M, Swahn ML. Replens versus dienoestrol

cream in the symptomatic treatment

of vaginal atrophy in postmenopausal women.

Maturitas. 1996; 23(3):259-263.

https://doi.org/10.1016/0378-5122(95)00955-8

Nachtigall LE. Comparative study: Replens versus

local estrogen in menopausal women. Fertil Steril.

; 61(1):178-180.

https://doi.org/10.1016/s0015-0282(16)56474-7

Jozkowski KN, Herbenick D, Schick V, Reece M,

Sanders SA, Fortenberry JD. Women’s perceptions

about lubricant use and vaginal wetness

during sexual activities. J Sex Med. 2013;

(2):484-492.

https://doi.org/10.1111/jsm.12022

Hickey M, Saunders C, Partridge A, Santoro N, Joffe

H, Stearns V. Practical clinical guidelines for

assessing and managing menopausal symptoms

after breast cancer. Ann Oncol. 2008; 19(10):1669-

https://doi.org/10.1093/annonc/mdn353

Lester J, Pahouja G, Andersen B, Lustberg M.

Atrophic vaginitis in breast cancer survivors:

a difficult survivorship issue. J Pers Med. 2015;

(2):50-66. https://doi.org/10.3390/jpm5020050

Tomihata K, Ikada Y. Crosslinking of hyaluronic

acid with water-soluble carbodiimide. J Biomed

Mater Res. 1997; 37(2):243-251.

h t t p s : / / d o i . o r g / 1 0 . 1 0 0 2 / ( s i c i ) 1 0 9 7 -

(199711)37:2<243::aid-jbm14>3.0.co;2-f

Chen J, Geng L, Song X, Li H, Giordan N, Liao

Q. Evaluation of the efficacy and safety of

hyaluronic acid vaginal gel to ease vaginal

dryness: a multicenter, randomized, controlled,

open-label, parallel-group, clinical trial. J Sex

Med. 2013; 10(6):1575-1584.

https://doi.org/10.1111/jsm.12125

Jokar A, Davari T, Asadi N, Ahmadi F, Foruhari

S. Comparison of the Hyaluronic Acid Vaginal

Cream and Conjugated Estrogen Used in

Treatment of Vaginal Atrophy of Menopause Women:

A Randomized Controlled Clinical Trial. Int J

Community Based Nurs Midwifery. 2016; 4(1):69-78.

Espitia-De La Hoz FJ; Orozco-Gallego H; Echeverri-

Ocampo L. Terapia hormonal y no hormonal en

la vaginitis atrófica posmenopáusica: cura y

satisfacción a mediano y a largo plazo de los síntomas.

Rev. Col. De Menopausia. 2016; 22(1):8-17.

Mitchell CM, Guthrie KA, Larson J, Diem S, La-

Croix AZ, Caan B, et al. Sexual frequency and

pain in a randomized clinical trial of vaginal

estradiol tablets, moisturizer, and placebo in

postmenopausal women. Menopause. 2019;

(8):816-822.

https://doi.org/10.1097/GME.0000000000001341

Grimaldi EF, Restaino S, Inglese S, Foltran L, Sorz A,

Di Lorenzo G, et al. Role of high molecular weight

hyaluronic acid in postmenopausal vaginal

discomfort. Minerva Ginecol. 2012; 64(4):321-329

Ekin M, Yaşar L, Savan K, Temur M, Uhri M, Gencer

I, et al. The comparison of hyaluronic acid

vaginal tablets with estradiol vaginal tablets in

the treatment of atrophic vaginitis: a randomized

controlled trial. Arch Gynecol Obstet. 2011;

(3):539-543.

https://doi.org/10.1007/s00404-010-1382-8

Boselli F, Petrella E, Campedelli A, Muzi M, Rullo

V, Ascione L, et al. Efficacy and tolerability of

fitostimoline (vaginal cream, ovules, and vaginal

washing) and of benzydamine hydrochloride

(tantum rosa vaginal cream and vaginal washing)

in the topical treatment of symptoms of bacterial

vaginosis. ISRN Obstet Gynecol. 2012; 2012:1-5.

https://doi.org/10.5402/2012/183403

Sanguigno L, Minale M, Vannini E, Arato G, Riccio

R, Casapullo A, et al. Oligosaccharidic fractions

derived from Triticum vulgare extract accelerate

tissutal repairing processes in in vitro and in

vivo models of skin lesions. J Ethnopharmacol.

; 159:198-208.

https://doi.org/10.1016/j.jep.2014.10.051

D’Agostino A, Pirozzi AVA, Finamore R, Grieco F,

Minale M, Schiraldi C. Molecular Mechanisms at

the Basis of Pharmaceutical Grade Triticum vulgare

Extract Efficacy in Prompting Keratinocytes

Healing. Molecules. 2020; 25(3):1-14.

https://doi.org/10.3390/molecules25030431

Sanguigno L, Casamassa A, Funel N, Minale M,

Riccio R, Riccio S, et al. Triticum vulgare extract

exerts an anti-inflammatory action in two in vitro

models of inflammation in microglial cells. PLOS

ONE. 2018; 13(6):1-7.

https://doi.org/10.1371/journal.pone.0197493

Funel N, Dini V, Janowska A, Loggini V, Minale M,

Grieco F, et al. Triticum vulgare extract modulates

protein-kinase b and matrix metalloproteinases

protein expression in bv-2 cells: Bioactivity

on inflammatory pathway associated with molecular

mechanism wound healing. Mediators of

Inflammation. 2020; 2020: 1-13.

https://doi.org/10.1155/2020/2851949

Antonucci I, Fiorentino G, Contursi P, Minale M,

Riccio R, Riccio S, et al. Antioxidant Capacity of

Rigenase®, a Specific Aqueous Extract of Triticum

vulgare. Antioxidants (Basel). 2018; 7(5):1-6.

https://doi.org/10.3390/antiox7050067

Boselli F, Petrella E, Campedelli A, Muzi M, Rullo

V, Ascione L, et al. Efficacy and Tolerability of

Fitostimoline (Vaginal Cream, Ovules, and VaginalWashing)

and of Benzydamine Hydrochloride

(Tantum Rosa Vaginal Cream and VaginalWashing)

in the Topical Treatment of Symptoms of

Bacterial Vaginosis. ISRN Obstetrics and Gynecology.

; 2012:1-5.

https://doi.org/10.5402/2012/183403

Parihar A, Parihar MS, Milner S, Bhat S. Oxidative

stress and anti-oxidative mobilization in burn

injury. Burns. 2008; 34(1):6-17.

https://doi.org/10.1016/j.burns.2007.04.009

Coutiño-Mata JJ, Cuenca-Pardo J, Álvarez-Díaz CJ,

Villaseñor Ferreira A. Manejo de las áreas donadoras

de injertos de piel tratadas con gasa con

Triticum vulgare vs gasa con petrolato. Cirugía

Plástica. 2002; 12(2):61-64.

Romanelli M, Macchia M, Panduri S, Paggi B,

Saponati-Dini V. Clinical evaluation of the efficacy

and safety of a medical device in various forms

containing Triticum vulgare for the treatment of

venous leg ulcers - a randomized pilot study.

Drug Des Devel Ther. 2015; 9:2787-2792.

https://doi.org/10.2147/DDDT.S82712

Martini P, Mazzatenta C, Saponati G. Efficacy

and tolerability of fitostimoline in two different

forms (soaked gauzes and cream) and citrizan

gel in the topical treatment of second-degree

superficial cutaneous burns. Dermatol Res

Pract. 2011; 2011:1-9.

https://doi.org/10.1155/2011/978291

Mollica G, Bonaccorsi G, Martinello R. Evaluation of

efficacy and tolerability of Fitostimoline vaginal

cream (Damor Farmaceutici) in the treatment

of vaginal inflammation and vulvar dystrophy:

A double-blind randomized controlled trial.

Gazzetta Medica Italiana Archivio per le Scienze

Mediche. 2008; 167(3):87-95.

Mainini G. Treatment of Vaginal Atrophy with the

Aqueous Extract of Triticum vulgare: Comparison

between Different Pharmaceutical Forms.

ARCH Women Health Care. 2020; 3(3):1-4.

Rashidi-Fakari F, Simbar M, Nasab MB, Ghazanfarpour

M, Rashidi-Fakari F. A Review of Pharmacological

Treatments for Vaginal Atrophy in

Postmenopausal Women in Iran. J Menopausal

Med. 2020; 26(2):104-111.

https://doi.org/10.6118/jmm.19021

Ghazanfarpour M, Sadeghi R, Roudsari RL. The

application of soy isoflavones for subjective

symptoms and objective signs of vaginal atrophy

in menopause: A systematic review of randomised

controlled trials. J Obstet Gynaecol. 2016;

(2):160-171.

https://doi.org/10.3109/01443615.2015.1036409

Bouchard C. Herbal alternatives as substitutes for

hormone therapy in urogenital atrophy: scientific

evidence is needed. Menopause. 2008; 15(1):12-

https://doi.org/10.1097/gme.0b013e31815b7553

Reed SD, Newton KM, LaCroix AZ, Grothaus LC,

Grieco VS, Ehrlich K. Vaginal, endometrial, and

reproductive hormone findings: randomized,

placebo-controlled trial of black cohosh, multibotanical

herbs, and dietary soy for vasomotor

symptoms: the Herbal Alternatives for Menopause

(HALT) Study. Menopause. 2008; 15(1):51-58.

DOI: 10.1097/gme.0b013e318057787f

Castelo-Branco C, Hernández-Angeles LCE. Síndrome

genitourinario de la menopausia: revisión.

Rev. Col. De Menopausia. 2015; 21(2):25-36.

Sandhu RS, Wong TH, Kling CA, Chohan KR. In

vitro effects of coital lubricants and synthetic

and natural oils on sperm motility. Fertil Steril.

; 101(4):941-944.

https://doi.org/10.1016/j.fertnstert.2013.12.024

Brown JM, Hess KL, Brown S, Murphy C, Waldman

AL, Hezareh M. Intravaginal practices and risk

of bacterial vaginosis and candidiasis infection

among a cohort of women in the United States.

Obstet Gynecol. 2013; 121(4):773-780.

https://doi.org/10.1097/AOG.0b013e31828786f8

Sarebani Z, Alimoradi Z, Aali E, Mirzadeh M, Chegini

V, Abbaspour M, et al. Investigating the effect of

vitamin D vaginal suppository on sexual function

among postmenopausal women: study protocol

for a randomized controlled trial. BMC Women’s

Health. 2020; 20(27):1-8.

https://doi.org/10.1186/s12905-020-00899-6

Lee A, Lee MR, Lee HH, Kim YS, Kim JM, Enkhbold

T, et al. Vitamin D Proliferates Vaginal Epithelium

through RhoA Expression in Postmenopausal

Atrophic Vagina tissue. Molecules and Cells. 2017;

(9):677-684.

https://doi.org/10.14348/molcells.2017.0026

Riazi H, Ghazanfarpour M, Taebi M, Abdolahian

S. Effect of Vitamin D on the Vaginal Health of

Menopausal Women: A Systematic Review. J

Menopausal Med. 2019; 25(3):109-116.

https://doi.org/10.6118/jmm.19194

Rad P, Tadayon M, Abbaspour M, Latifi SM, Rashidi

I, Delaviz H. The effect of vitamin D on vaginal

atrophy in postmenopausal women. Iran J Nurs

Midwifery Res. 2015; 20(2):211-215.

Keshavarzi Z, Janghorban R, Alipour S, Tahmasebi

S, Jokar A. The effect of vitamin D and E vaginal

suppositories on tamoxifen-induced vaginal

atrophy in women with breast cancer. Support

Care Cancer. 2019; 27(4):1325-1334.

https://doi.org/10.1007/s00520-019-04684-6

Ziagham S, Abbaspour Z, Abbaspour MR. The

comparison betweenthe effects of hyaluronic

acid vaginal suppository and vitamin E on the

treatment of atrophic vaginitis in menopausal

women. J Arak Uni Med Sci. 2012; 15(6):57-64.

Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis

D, Athanasiou S. The Genitourinary Syndrome of

Menopause: An Overview of the Recent Data.

Cureus. 2020; 12(4):1-9.

https://doi.org/10.7759/cureus.7586

Costantino D, Guaraldi C. Effectiveness and safety

of vaginal suppositories for the treatment of the

vaginal atrophy in postmenopausal women: an

open, non-controlled clinical trial. Eur Rev Med

Pharmacol Sci. 2008; 12(6):411-416.

Parnan-Emamverdikhan A, Golmakani N, Tabassi

SA, Hassanzadeh M, Sharifi N, Shakeri MT. A

survey of the therapeutic effects of Vitamin E

suppositories on vaginal atrophy in postmenopausal

women. Iran J Nurs Midwifery Res. 2016;

(5):475-481.

https://doi.org/10.4103/1735-9066.193393

Golmakani N, Parnan-Emamverdikhan A, Zarifian A,

Sajadi-Tabassi SA, Hassanzadeh M. Vitamin E as

alternative local treatment in genitourinary syndrome

of menopause: a randomized controlled

trial. Int Urogynecol J. 2019; 30(5):831-837.

https://doi.org/10.1007/s00192-018-3698-z

Hobson R. Vitamin E and wound healing: an evidence-

based review. Int Wound J. 2016; 13(3):331-

https://doi.org/10.1111/iwj.12295

The North American Menopause Society. Management

of symptomatic vulvovaginal atrophy: 2013

position statement of The North American Menopause

Society. Menopause. 2013; 20(9):888-902.

https://doi.org/10.1097/GME.0b013e3182a122c2

Goetsch MF, Lim JY, Caughey AB. A Practical Solution

for Dyspareunia in Breast Cancer Survivors:

A Randomized Controlled Trial. J Clin Oncol. 2015;

(30):3394-3400.

https://doi.org/10.1200/JCO.2014.60.7366

Arunkalaivanan A, Kaur H, Onuma O. Laser therapy

as a treatment modality for genitourinary

syndrome of menopause: a critical appraisal of

evidence. Int Urogynecol J. 2017; 28(5):681-685.

https://doi.org/10.1007/s00192-017-3282-y

Archivos de Medicina Volumen 21 Nº 2 - Julio-Diciembre de 2021

Universidad de Manizales - Facultad de Ciencias de la Salud

Cruz VL, Steiner ML, Pompei LM, Strufaldi R,

Fonseca FLA, Santiago LHS, et al. Randomized,

double-blind, placebo-controlled clinical trial for

evaluating the efficacy of fractional CO2 laser

compared with topical estriol in the treatment

of vaginal atrophy in postmenopausal women.

Menopause. 2018; 25(1):21-28.

https://doi.org/10.1097/GME.0000000000000955

Sokol ER, Karram MM. An assessment of the

safety and efficacy of a fractional CO2 laser

system for the treatment of vulvovaginal atrophy.

Menopause. 2016; 23(10):1102-1107.

https://doi.org/10.1097/GME.000000000000070

Filippini M, Luvero D, Salvatore S, Pieralli A, Montera

R, Plotti F, et al. Efficacy of fractional CO2

laser treatment in postmenopausal women with

genitourinary syndrome: a multicenter study.

Menopause. 2020; 27(1):43-49.

https://doi.org/10.1097/GME.0000000000001428

Millheiser LS, Pauls RN, Herbst SJ, Chen BH. Radiofrequency

treatment of vaginal laxity after

vaginal delivery: nonsurgical vaginal tightening.

J Sex Med. 2010; 7(9):3088-3095.

https://doi.org/10.1111/j.1743-6109.2010.01910.x

Wańczyk-Baszak J, Woźniak S, Milejski B, Paszkowski

T. Genitourinary syndrome of menopause

treatment using lasers and temperature-controlled

radiofrequency. Prz Menopauza lny. 2018;

(4):180-184.

https://doi.org/10.5114/pm.2018.81743

Espitia-De La Hoz FJ. Efficacy and tolerance of

policresulen in the treatment of the genitourinary

syndrome of menopause. Int J Fam Commun Med.

; 3(3):132-136.

https://doi.org/10.15406/ijfcm.2019.03.00145

Espitia-De La Hoz FJ. Efectividad y seguridad del

policresuleno en el tratamiento del síndrome

genitourinario de la menopausia. Estudio controlado

y aleatorizado. Arch Med (Manizales). 2020;

(2):282-294.

https://doi.org/10.30554/archmed.20.2.3756

Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi

D, Gyftopoulou K, Skarmoutsou N, et al.

Health benefits of probiotics: a review. ISRN Nutr.

; 2013:1-8. https://doi.org/10.5402/2013/481651

Falagas ME, Betsi GI, Athanasiou S. Probiotics

for the treatment of women with bacterial vaginosis.

Clin Microbiol Infect. 2007; 13(7):657-664.

https://doi.org/10.1111/j.1469-0691.2007.01688.x

Muhleisen AL, Herbst-Kralovetz MM. Menopause

and the vaginal microbiome. Maturitas. 2016;

:42-50.

https://doi.org/10.1016/j.maturitas.2016.05.015

Pushkar D, Gvozdev MY. Dynamics of symptoms

of genitourinary menopausal syndrome and

the frequency of recurrence of lower urinary

tract infection in women in peri-and postmenopausal

patients with combined therapy with

Trioginal. Gynecology. 2018; 20(6):67-72.

https://doi.org/10.26442/20795696.2018.6.180119

Kuzmenko-Kuzmenko AV, Kuzmenko-Kuzmenko

VV, Gyaurgiev-Gyaurgiev TA. Experience of

application of hormonal and probiotic therapy

in the complex treatment of women in peri- and

postmenopausal with chronic recurrent bacterial

cystitis in the background of vulvovaginal

atrophy. Urologia. 2019; 3:66-71.

DOI: 10.18565/urology.2019.3.66-71

The NAMS 2017 Hormone Therapy Position Statement

Advisory Panel. The 2017 hormone therapy

position statement of The North American Menopause

Society. Menopause. 2017; 24(7):728-753.

https://doi.org/10.1097/GME.0000000000000921

Palacios S, Cancelo-Hidalgo MJ, González SP,

Manubens M, Sánchez-Borrego R. Síndrome genitourinario

de la menopausia: recomendaciones

de la Sociedad Española de Ginecología y Obstetricia.

Prog Obstet Ginecol. 2019; 62(2):141-148.

https://doi.org/10.20960/j.pog.00182